TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genetic Signatures Ltd. ( (AU:GSS) ) just unveiled an announcement.
Genetic Signatures Ltd. announced it will release its FY 25 annual results on August 25, 2025, followed by an investor webinar hosted by CEO Allison Rossiter and CFO Karl Pechmann. This event is an opportunity for stakeholders to gain insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (AU:GSS) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
More about Genetic Signatures Ltd.
Genetic Signatures Ltd. is a global molecular diagnostics company specializing in the development and commercialization of its proprietary 3base® platform technology. The company designs and manufactures real-time PCR-based products under the EasyScreen™ brand for the detection of infectious diseases. Its primary market focus includes major hospitals and pathology laboratories engaged in infectious disease screening, leveraging strong sales from COVID-19 related products and expanding interest in gastroenteritis and other infectious pathogen screening solutions.
Average Trading Volume: 110,523
Technical Sentiment Signal: Sell
Current Market Cap: A$72.68M
For detailed information about GSS stock, go to TipRanks’ Stock Analysis page.